Based on these in vitro and in vivo studies showing that monotherapy with TRAIL ligands or TRAIL receptor antibodies are not sufficient to cause tumor regression and sustained control of tumor growth in the majority of childhood cancers, a number of different combination therapies were developed. The gene discussed is TNFSF10; the disease is neoplasm.